AHRQ Examines Impact of Payment Policies on Clinical Trials
AHRQ Examines Impact of Payment Policies on Clinical Trials
The Agency for Healthcare Research and Quality (AHRQ) has released a draft paper examining the impact of changes in payment policies on clinical trials. The report discusses the relationship between third-party payments and the recruitment and retention of participants in clinical trials. Among the conclusions of the report: payment policies do affect evidence development in that their impact on clinical trial enrollment results in slower accrual, longer time to complete studies, and the occasional early termination of a study due to a lack of participation. Further, the reports suggest that better coordination among government agencies and between government, third-party payors, sponsors, and trial sites is necessary. Comments on the report are due Jan. 23.
Information: Go to http://www.ahrq.gov/clinic/ta/paypolicy/paypolicy.pdf
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
